

Pierre SOUBEYRAN Professeur des universités Université de Bordeaux

Pierre Soubeyran est Professeur des Universités (Université de Bordeaux) et Médecin spécialiste des Centres de Lutte contre le Cancer à l'Institut Bergonié à Bordeaux (Département d'Oncologie Médicale). Il a obtenu son Doctorat en Médecine en 1989, son Diplôme d'Études Spéciales en 1989 et son Doctorat de Sciences Biologiques et Médicales (Option : Biologie - Santé) en 1996 suite à ses recherches en hématologie au MD Anderson Cancer Centre (Houston, USA).

Ses travaux de recherche clinique portent sur les lymphomes non-hodgkiniens et la prise en charge des cancers des patients âgés. Ses travaux en oncogériatrie visent à proposer des approches cliniques et sociales adaptées à ces patients âgés.

En 2012, il est Directeur du SIRIC BRIO (Bordeaux Recherche Intégrée Oncologie), labellisé par l'Institut National du Cancer. Le SIRIC BRIO est porté par l'Institut Bergonié et regroupe des équipes du CHU, de l'Université de Bordeaux, du CNRS et de l'INSERM.

Il est également Co-coordonnateur de l'Unité de Coordination en Oncogériatrie (UCOG), labellisée par l'Institut National du Cancer.

En 2016, il est nommé Directeur de l'Unité INSERM U1218 ACTION (Actions for Oncogenesis understanding and Target Identification in Oncology).

Depuis mai 2016, il est Directeur de la Recherche de l'Institut Bergonié.

Il est membre de plusieurs sociétés savantes, notamment : American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), European Society of Medical Oncology (ESMO), European Society of Therapeutic Radiology and Oncology (ESTRO), International Society of Geriatric Oncology (SIOG).

Principales publications

- Mazroui Y, Mathoulin-Pélissier S, **Soubeyran P**, Rondeau V. General joint frailty models for recurrent event data with a dependent terminal event: application to follicular lymphoma data. *Stat Med* 2012;31:1162-76.
- **Soubeyran P**, Henriques de Figueredo B, Soubeyran I, Mertens C, Cazeau AL. Therapeutic strategies in elderly and very elderly patients. *Best Pract Res Clin Haematol* 2012;25:91-100.
- **Soubeyran P**, Fonck M, Rainfray M, Blanc-Bisson C, Mertens C, Imbert Y, Cany L, Vogt L, Dauba J, Palis R, Andriamampionona F, Houédé N, Floquet A, Chomy F, Brouste V, Ravaud A, Bellera C, Rainfray M. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. *J Clin Oncol* 2012; 30(15): 1829-34.
- Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, **Soubeyran P**. Towards a screening tool in geriatric oncology: methodological and clinical considerations of the G8 screening tool. *Ann Oncol* 2012;23:2166-72.
- Delva F, **Soubeyran P**, Rainfray M, Mathoulin-Pélissier S. Referral of elderly cancer patients to specialists: action proposals for general practitioners. *Cancer Treat Rev* 2012;38:935-41.
- Dupuis J, Riedinger AB, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, **Soubeyran P**, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M. Impact of [18F]Fluorodeoxyglucose PET response evaluation in high-tumor burden follicular lymphoma patients treated with immuno-chemotherapy (a prospective study from the GELA & GOELAMS). *J Clin Oncol* 2012;30:4317-22.
- Mathoulin-Pélissier S, Bellera C, Rainfray M, **Soubeyran P**. Strategies for determining the best geriatric screening method for frailty. *Lancet Oncol* 2013;14:e1-2.
- Allart P, Cousson-Gélie F, **Soubeyran P**. Are psychosocial factors associated with quality of life in patients with haematological cancer? A critical review of the literature. *PsychoOncology* 2013;22:241-9.
- Morschhauser F, Radford J, Van Hoof A, Vitolo U, Rohatiner AZS, Salles G, **Soubeyran P**, Tilly H, Bischof-Delaloye A, van Putten WLJ, Klystra JW, Hagenbeek A for the FIT Investigators. Yttrium-90 ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular Non-Hodgkin's lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase 3 first-line indolent trial in 414 patients. *J Clin Oncol* 2013;31:1977-83.
- Bellera C, Praud D, Petit-Monéger A, McKelvie-Sebileau P, **Soubeyran P**, Mathoulin-Pélissier S. Barriers to inclusion of older adults in randomised clinical trials on Non-Hodgkin's lymphoma: a systematic review. *Cancer Treat Rev* 2013;39:212-7.

- **Soubeyran P.** From suboptimal to optimal treatment in older patients with cancer. *J Geriatr Oncol* 2013, 4: 291-3.
- Hoppe S, Rainfray M, Fonck M, Hoppenreys L, Blanc JF, Ceccaldi J, Mertens C, Blanc-Bisson C, Imbert Y, Cany L, Vogt L, Dauba J, Houédé N, Bellera C, Floquet A, Fabry MN, Ravaud A, Chakiba C, Mathoulin-Pélissier S, **Soubeyran P.** Prognostic factors of functional decline in elderly cancer patients receiving first-line chemotherapy. *J Clin Oncol* 2013;31:3877-82
- **Soubeyran P,** Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, Albrand G, Servent V, St Jean O, van Pragh I, Kurtz JE, Périn S, Verhaeghe JL, Terret C, Desauw C, Girre V, Mertens C, Droz JP, Mathoulin-Pélissier S, Rainfray M, for the ONCODAGE investigators. Screening for vulnerability in elderly cancer patients: Validation of the G8 screening test. *Plos One* 2014;9:e115060.
- Morrison VA, Hamlin P, **Soubeyran P,** Stauder R, Wadhwa P, Aapro M, Lichtman S. Diffuse large B-cell lymphoma in the elderly : Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology Expert Position Paper. *J Geriatr Oncol* 2015;6:141-52.
- Terret C, Albrand G, Rainfray M, **Soubeyran P.** Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review. *Expert Rev Hematol* 2015;8:329-41.
- Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney D, **Soubeyran P,** Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW. Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. *J Clin Oncol* 2015; 33:1482-90.
- Morrison VA, Hamlin P, **Soubeyran P,** Stauder R, Wadhwa P, Aapro M, Lichtman SM. Approach to therapy of Diffuse Large B-Cell Lymphoma in the Elderly: The International Society of Geriatric Oncology (SIOG) Expert Position Commentary. *Ann Oncol* 2015;26:1058-68.
- Bourdel-Marchasson I, Diallo A, Bellera C, Blanc-Bisson C, Durrieu J, Germain C, Mathoulin-Pélissier S, **Soubeyran P,** Rainfray M, Fonck M, Doussau A. One-year mortality in older patients with cancer: development and external validation of an MNA-based prognostic model. *PlosOne* 2016;11:e0148523.
- Martinez-Tapia C, Canoui-Poitrine F, Bastuji-Garin S, **Soubeyran P,** Mathoulin-Pelissier S, Tournigand C, Paillaud E, Laurent M, Audureau E, ELCAPA Study Group. Optimizing the G8 screening tool for older patients with cancer: diagnostic performance and validation of a six-item version. *The Oncologist* 2016 Feb;21(2):188-95.
- Petit-Monéger A, Rainfray M, **Soubeyran P,** Bellera CA, Mathoulin-Pélissier S. Detection of frailty in elderly cancer patients: improvement of the G8 screening test. *J Geriatr Oncol* 2016;7:99-107.
- Bron D, **Soubeyran P,** Fulop T on behalf of the SWG "Aging and Hematology" of the EHA. Innovative approach of older patients with malignant hemopathies. *Haematologica* 2016;101:893-5.
- Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, **Soubeyran P,** Gomes Da Silva M, Mounier C,, Offner F, Dupuis J, Caballero D, Canioni D, Marlton P, Delarue R, Zachee P , Seymour J, Salles G, Tilly H. Risk factors and outcomes of follicular lymphoma patients with histological transformation after response to first-line immunochemotherapy in the PRIMA study. *J Clin Oncol* 2016;34:2575-82.
- Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, **Soubeyran P,** Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles MP, Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R. Primary CNS Lymphoma at first relapse/progression: characteristics, management and outcome of 256 patients from the French LOC Network. *Neuro-Oncology* 2016;18:1297-303.
- Duc S, Rainfray M, **Soubeyran P,** Fonck M, Blanc JF, Ceccaldi J, Cany L, Brouste V, Mathoulin-Pélissier S. Predictive factors of depressive symptoms of elderly patients with cancer receiving first-line chemotherapy. *Psycho-Oncology* 2016 Feb 23, doi: 10.1002/pon.4090, In Press.
- **Soubeyran P,** Terret C, Bellera C, Bonnetain F, Saint Jean O, Galvin A, Chakiba C, Zwolakowski MD, Mathoulin-Pélissier S, Rainfray M. Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial. *BMC Cancer* 2016, In Press.
- Kurtz JE, **Soubeyran P,** Michallet M, Luporsi E, Albrand H. Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients: a subanalysis of the BiOsimilaRs in the management of anemia secondary to chemotherapy in Haematology and Oncology observational study (ORHEO). *Oncotargets and Therapy* 2016, In Press.
- Pallardy A, Maisonneuve H, Champion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Henry Jardel E, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Wegener WA, Goldenberg DM, Lamy T, **Soubeyran P.** Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly DLBCL patients: a GOELAMS/LYSA phase II prospective trial. *The Lancet Haematology* 2016, In Press.
- Villar VH, Nguyen TL, Terés S, Bouchecareilh M, Salin B, Bodineau C, Priault M, **Soubeyran S,** Durán RV. mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation. *Nat Comm* 2016, In Press.